Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-451a miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RDM0006H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Serum, Plasma-EDTA, Whole blood, PBMC, Cell culture lysates

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 5.7%

Inter-assay (Run-to-Run)

n = 5,
CV = 6.3%

Spiking Recovery


Dilution Linearity



Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.


Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-451a isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology, Neurodegenerative disease, Stroke


MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

In the human genome, miR-451a is encoded in proximity to miR-144 in chromosome region 17q11.2 and its biogenesis occurs via a non-canonical pathway that depends on Ago2 protein. Many studies have established that miR-451a is widely dysregulated in human malignancies, including papillary thyroid carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, gastric cancer, breast cancer, glioma and cutaneous basal cell carcinoma. Serum exosomal miR-451a has diagnostic utility in diffuse large B-cell lymphoma and hepatocellular carcinoma. Furthermore, miR-451a was downregulated in non-small cell lung cancer (NSCLC) tissues and lung cancer cells.

MicroRNA-451a is a cell metabolism-related miRNA. In glioma cells, miR‐451a can regulate glucose transporters such as GLUT1 on the cell membrane to downregulate glucose metabolism and prevent energy supply to cancer cells. In human gastric cancer cells, miR-451a expression was increased by high glucose treatment and decreased significantly when the glucose level was low. It was found that exosomal miR-451a could serve as an indicator of poor prognosis of post-surgery gastric cancer patients and that increased secretion of exosomal miR-451a could be triggered in a low glucose condition.

Besides cancer, miR-451a was reported to be associated with neuronal maturation processes in vitro and in vivo. A regulatory role of miR-451a in brain has been suggested by the studies showing that microparticles derived from cerebrospinal fluid (CSF) of patients in the acute stages of traumatic brain injury (TBI) are specifically enriched in miR-451a. Moreover, miR-451a was identified as a biomarker in pathogenesis and prognosis of acute ischemic stroke (AIS) patients and in transient ischemic attack (TIA) patients. It was also published that miR-451a was downregulated in differentiated myoblasts and the findings suggest an inhibitory role of miR-451a in myogenesis.

Summary References (17)

References to miR-451a

  • Uchida, Akifumi, et al. "Regulation of KIF2A by Antitumor miR-451a Inhibits Cancer Cell Aggressiveness Features in Lung Squamous Cell Carcinoma." Cancers 11.2 (2019): 258.
  • Minna, Emanuela, et al. "miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma." Oncotarget 7.11 (2016): 12731.
  • Takahasi, Kunihiko, et al. "Usefulness of exosome‐encapsulated microRNA‐451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma." Journal of Hepato‐Biliary‐Pancreatic Sciences 25.2 (2018): 155-161.
  • Xu, Ke, et al. "MiR-451a suppressing BAP31 can inhibit proliferation and increase apoptosis through inducing ER stress in colorectal cancer." Cell death & disease 10.3 (2019): 152.
  • Liu, Feng, et al. "Increased T‐helper 17 cell differentiation mediated by exosome‐mediated micro RNA‐451 redistribution in gastric cancer infiltrated T cells." Cancer science 109.1 (2018): 65-73.
  • Shen, Yong, et al. "MiR-451 as a new tumor marker for gastric cancer." Oncotarget 8.34 (2017): 56542.
  • Bergamaschi, Anna, and Benita S. Katzenellenbogen. "Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance." Oncogene 31.1 (2012): 39.
  • Godlewski, Jakub, et al. "microRNA-451: A conditional switch controlling glioma cell proliferation and migration." Cell Cycle 9.14 (2010): 2814-2820.
  • Sun, Hui, and Pingdong Jiang. "MicroRNA‐451a acts as tumor suppressor in cutaneous basal cell carcinoma." Molecular genetics & genomic medicine 6.6 (2018): 1001-1009.
  • Xiao, X. B., et al. "Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma." European review for medical and pharmacological sciences 23.4 (2019): 1620-1625.
  • Zhaoa, Shaorong, et al. "Exosomal miR-451a Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting LPIN1." Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 53.1 (2019): 19-35.
  • Shen, Y. Y., et al. "MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2." Eur. Rev. Med. Pharmacol. Sci 22 (2018): 5554-5561.
  • Guo, Hongbao, et al. "miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1." Tumor Biology 37.10 (2016): 13751-13761.
  • Trattnig, Christa, et al. "MicroRNA-451a overexpression induces accelerated neuronal differentiation of Ntera2/D1 cells and ablation affects neurogenesis in microRNA-451a-/-mice." PloS one 13.11 (2018): e0207575.
  • Patz, Silke, et al. "More than cell dust: microparticles isolated from cerebrospinal fluid of brain injured patients are messengers carrying mRNAs, miRNAs, and proteins." Journal of neurotrauma 30.14 (2013): 1232-1242.
  • Giordano, Mauro, et al. "Circulating MiRNA-195-5p and-451a in Transient and Acute Ischemic Stroke Patients in an Emergency Department." Journal of clinical medicine 8.2 (2019): 130.
  • Munk, Rachel, et al. "Loss of miR-451a enhances SPARC production during myogenesis." PloS one 14.3 (2019): e0214301.
Related Products Docs